Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Complete title: A Mutli-Center, Open Label, Compassionate Use Extension study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Research Study Number 9703
 
Principal Investigator Mazyar Shadman
 
Phase III

Research Study Description

This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9703
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Leukemia, Chronic Lymphocytic (CLL); Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Leukemia, Lymphoid; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Immune System Diseases; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials